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The effects of superoxide dismutase treatment on infarct size, 
postischemic recovery of contractile function and tissue content of 
high energy phosphates were examined in a canine model of 
myocardial ischemia and reperfusion. Ischemia was induced by 
thrombotic occlusion of a coronary artery and reperfusion was 
achieved by intravenous thrombolysis. Average duration of ische-
mia was 90 min. Fifty closed chest anesthetized dogs were 
randomized to receive either superoxide dismutase (34,000 IV/min 
intravenously) or placebo, starting approximately 30 min before 
and continuing for 30 min into the reperfusion phase. 
Left ventricular ejection fraction and regional segmental short-
ening of the postischemic area were calculated from contrast 
angiograms after 4 h, 48 hand 1 week of reperfusion. Tissue 
content of high energy phosphates was determined from transmu-
Despite evidence of the generation of cytotoxic oxygen free 
radicals during myocardial ischemia and reperfusion, debate 
continues on the role of these radicals in myocardial stun-
ning, reperfusion arrhythmias and irreversible reperfusion 
injury (1). Accordingly, there is no consensus on the effect of 
therapy with superoxide dismutase, a free radical scavenging 
enzyme, in the setting of coronary reperfusion. 
The recovery of postischemic contractile function in dogs 
after 15 min of coronary occlusion is enhanced by pretreat-
ment with superoxide dismutase plus catalase (2-4). It 
remains to be determined whether this benefit persists if the 
administration offree radical scavengers is delayed until the 
time of reperfusion. When the duration of ischemia is 
prolonged to 2 h to produce subendocardial infarction, 
superoxide dis mutase given with catalase at the time of 
reperfusion does not alleviate the postischemic contractile 
dysfunction (5). 
The issue of infarct size limitation by administration of 
superoxide dis mutase remains unresolved as well, with some 
groups (6-10 consistently claiming beneficial effects and 
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ral biopsy after 4 h and 1 week. Infarct size was measured by 
planimetry of dye-stained heart slices. 
In the superoxide dismutase and placebo-treated groups, re-
spectively, the mortality rate was 25% and 16%, collateral flow 20 
± 10 and 23 ± 18 mIImin per 100 g, area at risk 25 ± 6% and 26 
± 7% of the left ventricle and infarct size 28 ± 19% and 36 ± 
27 % of the area at risk. Multiple regression analysis failed to show 
any beneficial effect of superoxide dismutase treatment on infarct 
size. Left ventricular ejection fraction, regional segmental short-
ening of the postischemic area and tissue content of high energy 
phosphates recovered to a similar extent and at a similar rate in 
both treated and placebo groups up to 1 week after reperfusion. 
Thus, in this model of coronary occlusion and reperfusion, 
superoxide dismutase treatment is of no benefit. 
(J Am Coli CardioI1991;18:224-30) 
others (5,12-16) reporting the lack thereof. Most of these 
discrepancies may be explained by differences in experimen-
tal design, although it is difficult to account for all the 
diversity in available data on this basis only (1). 
The purpose of this study was to examine the effects of 
superoxide dis mutase treatment in a coronary reperfusion 
setting mimicking the clinical situation. We used a canine 
model with 90 min of coronary occlusion, where reperfusion 
was achieved by thrombolysis and superoxide dismutase 
treatment was started simultaneously with the thrombolytic 
infusion. We specifically examined the effect of treatment on 
infarct size and postischemic recovery of contractile func-
tion. The latter was measured early (4 h) and late (48 hand 
1 week) so that the effects on myocardial stunning and the 
results of infarct size limitation might be differentiated. We 
also measured, as a corollary to contractile function, the 
myocardial content of high energy phosphates after 4 hand 
I week of reperfusion. 
Methods 
Surgical preparation. Fifty mongrel dogs of either gen-
der, weighing 14 to 27 kg, were premedicated with Hypnorm 
(10 mg fluanisone/0.2 mg fentanyl per ml), 0.25 mllkg body 
weight intramuscularly, and anesthetized with sodium pen-
tobarbital, 15 mg/kg intravenously. Mter endotracheal intu-
bation, the lungs were ventilated with a 50/50 mixture of 
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oxygen and room air with use of a Bird Mark 7 respirator. A 
cannula was inserted into the left external jugular vein for 
administration of drugs and fluids and into the left femoral 
artery for measurement of blood pressure and withdrawal of 
blood samples; angiographic catheters were advanced 
through the left common carotid artery. Electrocardio-
graphic (ECG) lead II was monitored on an oscilloscope. 
Study Protocol 
After baseline measurements of heart rate and blood 
pressure, contrast angiograms of the left ventricle and left 
coronary artery were obtained. Subsequently, a copper coil 
attached to a guide wire was advanced under fluoroscopic 
control through the carotid artery into the left anterior 
descending coronary artery. The formation of a thrombotic 
coronary occlusion within 5 to 10 min was confirmed by 
repeat angiography. 
Forty-five minutes later, hemodynamic measurements 
were repeated and regional myocardial blood flow was 
determined by injection of radioactive microspheres. A 
second left ventricular angiogram was obtained and persis-
tence of total coronary occlusion was verified by repeat 
coronary angiography. At this point, the dogs were random-
ized to receive either saline placebo or active treatment with 
superoxide dismutase (yeast-derived human recombinant 
copper-zinc superoxide dismutase, [Grunenthal]: specific 
activity 3,400 IV/mg) (17). The operators did not know the 
group assignment until data analysis was completed. The 
randomization protocol was such that the first 16 dogs would 
be equally divided between placebo and superoxide dismu-
tase groups. 
Thrombolysis. At 60 min after occlusion, thrombolytic 
infusion was started in all dogs. To this end, we used 
saruplase (recombinant unglycosylated full length human 
prourokinase [Grunenthal]; specific activity 164,000 U/mg) 
intravenously at a dose of 20 JLg/kg per min. The patency 
status of the left anterior descending coronary artery was 
checked angiographically every 5 to 10 min until a normal 
distal runoff of contrast dye was obtained; this occurred on 
average 30 min after the start of the thrombolytic therapy 
(see Results). The copper coil was then removed to prevent 
reocclusion after completion of the saruplase infusion, which 
was continued for a total of 60 min (that is, approximately 
30 min into the reperfusion period). 
Superoxide dismutase. Simultaneously with the throm-
bolytic infusion, either placebo or active treatment was 
started. Active treatment consisted of an intravenous infu-
sion of superoxide dismutase at 10 mg/min (34,000 IV/min) 
as a 6 mg/ml solution; in the placebo group, the same volume 
of saline solution was given. The superoxide dismutase or 
placebo infusion was continued for 1 h; superoxide dismu-
tase-treated dogs thus received a total dose of 600 mg (2.04 
million IV), which was about equally divided between the 
last 30 min of ischemia and the first 30 min of reperfusion. 
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Hemodynamic measurements, ventricular and coronary 
angiography and myocardial biopsy. In the first 16 dogs, the 
duration of reperfusion was limited to 4 h. At that time, 
hemodynamic measurements as well as ventricular and 
coronary angiography were repeated. The chest was then 
opened through a left lateral thoracotomy, the heart exposed 
and transmural needle biopsy specimens (Tru-Cut biopsy 
needle, Travenol Laboratories) were obtained in duplicate 
from the center of the postischemic left anterior descending 
artery area and from control myocardium supplied by the left 
circumflex coronary artery. The heart was subsequently 
arrested with intravenous potassium chloride and excised for 
further processing. In this group of experiments, there were 
no premature deaths. 
In the remaining 34 dogs, after reperfusion was estab-
lished, skin wounds were sutured and the dogs were re-
turned to their cage. Hemodynamic measurements as well as 
ventricular and coronary angiograms were repeated after 2 
days and again after 1 week during a final experiment that 
also included taking myocardial biopsy specimens as just 
described. 
Data Analysis 
Hemodynamics. Heart rate was calculated from the elec-
trocardiogram (ECG). Systolic and diastolic aortic blood 
pressure and left ventricular end-diastolic pressure were 
measured through a fluid-filled catheter and averaged over 
five consecutive beats. 
Infarct size. After excision of the heart both coronary 
ostia were cannulated as was the left anterior descending 
coronary artery at the site of previous occlusion, which was 
identified from the angiograms. This artery was perfused 
with Ringer's solution; the ostia were perfused at the same 
pressure with a mixture of Ringer's solution and Evans blue. 
After 2 min the left anterior descending artery perfusing 
solution was changed to a triphenyltetrazolium chloride 
solution (18) at 37°C for 10 min. Finally, the heart was fixed 
by perfusing the left anterior descending artery area for 
another 5 min with 2% glutaraldehyde and both coronary 
ostia with a mixture of 2% glutaraldehyde and Evans blue. 
After the right ventricle, the atria and valvular structures 
were removed, the isolated left ventricle was cut in 1 cm 
thick slices perpendicularly to the long axis. With use of 
calibrated color pictures of these slices, the left ventricular 
ring, the perfusion area of the left anterior descending 
coronary artery and the infarct area were reproduced with 
black ink on a transparent plastic sheet. Total left ventricular 
area, left anterior descending perfusion area and infarct area 
were calculated by automated planimetry (19), performed on 
the black ink reproductions of the original color pictures, 
with use of a Quantimet 900 image analyzer (Cambridge 
Instruments, Ltd.). The size of the left anterior descending 
perfusion area and of the infarct area were expressed as a 
percent of the total left ventricular area. 
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I placebo n=25 
/ fo\ n=25 ~ Figure 1. Experimental protocol. SOD = super-oxide dismutase. 
4 hrs reperfusion 1 wk reperfusion 4 hrs reperfusion 1 wk reperfusion 
n=8 n=17 n=8 n=17 
4 premature deaths 6 premature deaths 
8 dogs analyzed 13 dogs analyzed 8 dogs analyzed 
Collateral flow. Regional myocardial blood flow was 
measured with the tracer microsphere technique. We used 
microspheres with a 15 JLm diameter labeled with cerium-
141, tin-ll3, ruthenium-103 or niobium-95 (NEN Chemicals 
GmbH). Approximately 5.106 micro spheres per measure-
ment were injected into the left ventricular cavity through an 
angiographic pigtail catheter, while a reference blood sample 
was withdrawn from the descending aorta. At the end of an 
experiment, the left anterior descending and circumflex 
artery regions of the left ventricular slices (as indicated by 
the differential dye staining) were separated and subdivided 
into subepicardial, mid-myocardial and subendocardial seg-
ments, which were cut into mUltiple tissue samples. Regional 
myocardial blood flow was then quantified by the method of 
Domenech et al. (20). Transmural blood flow (mUmin per 
100 g) in the left anterior descending and circumflex artery 
regions was calculated as the weighted average of all the 
samples in the respective region. 
Ventricular wall motion. Global and regional left ventric-
ular wall motion were analyzed by computer processing of 
end-diastolic and end-systolic frames of the contrast angio-
gram (21). Global left ventricular ejection fraction was 
calculated and nine segments were identified for the study of 
segmental wall motion according to the method of Leighton 
et al. (22). As a measure of segmental wall motion in the left 
anterior descending artery area, we calculated the mean 
percent shortening of three hemiaxes that spanned the 
involved portion of the anterior wall. 
High energy phosphate content. The biopsy specimens 
were immediately frozen in liquid nitrogen and stored at 
-80°C until further processing. After lyophilization, homog-
enization, extraction with 0.6 N perchloric acid and neutral-
ization with potassium bicarbonate, the creatine phosphate 
and adenosine triphosphate (ATP) content were determined 
by using a bioluminescence assay (ATP bioluminescence 
CLS assay, Boehringer Pharma). For each measurement, 
the values from the two biopsy specimens were averaged. 
Statistics. Differences between superoxide dis mutase and 
placebo groups were evaluated by using multiple regression 
1 technical failure 
10 dogs analyzed 
analysis to correct for variables other than treatment alloca-
tion that may influence the outcome variable. When analyz-
ing infarct size, we (23) previously demonstrated that only 
the size of the area at risk (as a percent of the left ventricle) 
and the amount of collateral flow (as a percent of flow in the 
normally perfused area) have a significant predictive value; 
these variables were included in the mUltiple regression 
analysis together with the duration of reperfusion (4 h or 1 
week). 
In evaluating postischemic global and regional contractil-
ity, we corrected for heart rate, systolic blood pressure, left 
ventricular end-diastolic pressure, infarct size (as a percent 
of the left ventricle and of the area at risk) and global and 
regional contractility in preischemic control conditions. 
When comparing myocardial high energy phosphate content, 
we corrected for infarct size (as a percent ofthe area at risk) 
and for the high energy phosphate content in normally 
perfused myocardium. 
Calculation of the statistical power of the infarct size 
analysis was based on a univariate comparison between the 
two treatment groups using the Wilcoxon test for inference. 
Values are given as mean values ± 1 SD. Nominal signifi-
cance level was set at p = 0.05. For power calculations, we 
used the computer package Power Pack (24); all other 
calculations were done using the SAS statistical package 
(25). 
Results 
Mortality. Of the 50 dogs randomized, 10 died prema-
turely before completion of the protocol; 4 deaths were in 
the placebo group and 6 in the superoxide dismutase group. 
All of these premature deaths occurred in dogs that were 
meant to survive for 1 week. One additional experiment in 
the superoxide dismutase group could not be analyzed 
because of a technical failure with the dye perfusion staining. 
Thus, the final analysis involved 39 dogs (Fig. 1). 
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Table 1. Hemodynamic Data in 39 Dogs 
Reperfusion 
Control Occlusion 4h 48 h I Week 
Placebo (no.) 21 21 8 13 13 
HR (beats/min) 84 ± 29 106 ± 22 141 ± 40 79 ± 18 87 ± 21 
BP(mm Hg) 101 ± 19 107 ± 23 106 ± 21 89 ± 19 91 ± 21 
L VEDP (mm Hg) 7 ± 2 10 ± 5 9 ± 5 10 ± 5 9±4 
SOD (no.) 18 18 8 10 10 
HR (beats/min) 84 ± 24 109 ± 34 146 ± 30 84 ± 25 84 ± 24 
BP(mmHg) 101 ± 16 109 ± 19 97 ± 18 85 ± 16 96 ± 19 
L VEDP (mm Hg) 7 ± 2 9 ± 3 7±6 9±4 9 ± 3 
BP = systolic blood pressure: HR = heart rate; L VEDP = left ventricular end-diastolic pressure; SOD = superoxide dismutase. 
Duration of ischemia. The duration of ischemia was 90 ± 
11 min (range 76 to 119) in the placebo group and 90 ± 9 min 
(range 72 to 109) in the superoxide dismutase group. 
Hemodynamics (Table 1). There were no differences be-
tween the placebo and superoxide dismutase groups in heart 
rate, systolic blood pressure or left ventricular end-diastolic 
pressure at any time during the experimental protocol. In 
both groups, heart rate had iricreased after 4 h of reperfu-
sion. After 48 h, systolic blood pressure was somewhat 
lower. After 1 week of reperfusion, hemodynamic values 
were similar to those in the control period. 
Size of the area at risk. The perfusion bed of the left 
anterior descending coronary artery beyond the site of 
occlusion constituted 25 ± 6% (range 14% to 37%) ofthe left 
ventricle in the superoxide dis mutase group and 26 ± 7% 
(range 14% to 38%) in the placebo group. 
Collateral flow. During occlusion, transmural collateral 
blood flow in the left anterior descending artery area aver-
aged 20 ± 10 mllmin per 100 g (range 7 to 42) in the 
superoxide dismutase group and 23 ± 18 mllmin per 100 g 
(range 6 to 67) in the placebo group. 
Infarct size. Infarct size expressed as a percent of the 
area at risk was 28 ± 19% (range 3% to 69%) in the 





Figure 2. Relation between infarct size expressed 60 
as a percent of the area at risk (liP) and transmural 
collateral (COLL.) blood flow during left anterior 50 
descending coronary artery occlusion. Closed sym-
bols indicate the active treatment group; open sym- 40 
bois indicate the placebo group; triangles indicate 







85%) in the placebo group. The individual results for infarct 
size and transmural collateral flow are plotted in Figure 2. 
With infarct size as the dependent variable, mUltiple 
regression analysis was performed, including the size of the 
area at risk, amount of collateral blood flow, treatment 
allocation and duration of reperfusion. As a result of this 
analysis, we were unable to demonstrate any group effects 
(that is, infarct size was not influenced by the duration of 
reperfusion [4 h or 1 week] or by treatment allocation 
[superoxide dis mutase or placebo]). The only variables that 
were important in predicting the size of the infarct were the 
size of the area at risk and the level of collateral blood flow 
during ischemia. 
On the basis of a univariate analysis comparing the two 
treatment groups and using the Wilcoxon test for inference 
(significance level = 0.05), we calculated a statistical power 
for this study of approximately 30%, 58% and 75% for infarct 
size reductions (from placebo to superoxide dismutase) of 
30%,50% and 60%, respectively. The power associated with 
multiple regression analysis is usually higher than these 
values, but is subject to more uncertainty because of the 
uncertainty with which the coefficients of the other risk 






• • • 
i 
A • • o 
A 
• A o • 
• • • • 0 0 • o 
10 20 30 40 50 60 70 
(OlL. FLOW mllmin/100gr 
228 V ANHAECKE ET AL. 
SUPEROXIDE DISMUTASE AND REPERFUSION INJURY 
JACC Vol. 18, No. I 
July 1991 :224-30 
Table 2. Global and Regional Left Ventricular Contractility in 39 Dogs 
Superoxide Dismutase Placebo 
No. LVEF(%) RSS(%) No. LVEF (%) RSS (%) 
Control 18 58 ± 7 28 ± 6 21 61 ± 9 30 ± 10 
Occlusion 18 36 ± 7 -6 ± 8 21 39 ± 12 -7 ± 13 
Reperfusion 
4h 8 30 ± 13 -IO±II 8 23 ± 14 -9 ± 9 
48 h 10 40 ± 17 10 ± 14 13 45 ± 12 5 ± 14 
I wk 10 55 ± 7 19 ± 13 13 52 ± 12 8 ± 16 
L VEF = global left ventricular ejection fraction; RSS = regional segmental shortening in the area of the left anterior descending coronary artery. 
Global and regional (anterior wall) left ventricular contrac-
tility (Table 2). After 4 h of reperfusion, the decrease in 
global left ventricular ejection fraction and the outward 
systolic bulging of the postischemic area persisted in both 
the treated and placebo groups. Subsequently there was a 
gradual recovery of the ejection fraction in both groups. 
Regional wall motion in the left anterior descending artery 
area also recovered to a limited and variable degree. 
Multiple regression analysis correcting for hemodynamic 
variables and wall motion in control conditions did not 
reveal any beneficial effect of superoxide dismutase treat-
ment. The extent and the speed of recovery were not 
enhanced in treated dogs. 
Myocardial high energy phosphate content (Table 3). 
Tissue ATP content, depressed after 4 h of reperfusion, was 
partially restored 1 week later, whereas tissue creatine 
phosphate content decreased during this time interval. After 
correcting for infarct size and high energy phosphate content 
in normally perfused myocardium, no effect of superoxide 
dismutase treatment could be demonstrated either after 4 h 
or 1 week of reperfusion. 
Discussion 
Experimental protocol. Assuming that irreversible reper-
fusion injury in the coronary occlusion/reperfusion setting 
exists, the discrepancies among various studies (5-16) ex-
amining the effect of treatment with free radical scavengers 
may in part be explained by differences in experimental 
design (I). In the present study, we tried to avoid some of the 
more obvious pitfalls. A relatively large number of dogs 
were randomized between placebo and active treatment and 
the investigators did not know the treatment allocation until 
completion of data analysis. The time frame using 90 min of 
ischemia followed by reperfusion is well accepted in canine 
studies (6,7,10,14-16) and is not too distant from the clinical 
situation; the minimal duration of 4 h reperfusion brings the 
model within the reliable range for tetrazolium staining 
(18,26,27). Reperfusion by intravenous administration of a 
thrombolytic agent not only resembles the clinical situation, 
but also provides gradual reperfusion, preventing possible 
deleterious effects of abruptly removing a clamp (28,29). 
We did not measure blood levels of superoxide dismutase 
and the drug was administered intravenously, in contrast to 
the intraatrial delivery route in some other studies; the 
timing (starting 30 min before reperfusion) and the dosage (a 
total of 2 x 106 IV over 60 min) of the intravenous super-
oxide dis mutase administration, however, should have pro-
vided blood levels well within the acceptable range through-
out the early phase of reperfusion. 
We used the superoxide dis mutase molecule in its non-
conjugated form, which is known to have a short half-life of 
10 to 20 min (1,12). Thus, protection from oxygen radicals 
may have been insufficient or absent during the later phases 
of reperfusion if at that stage oxygen radicals were generated 
(for example, by infiltrating neutrophils). Recent studies 
(10,16) have addressed this issue of duration of treatment by 
using superoxide dismutase conjugated to polyethylene gly-
col, thereby extending the half-life to 30 h; the results of 
these studies were discordant with respect to the effect of the 
drug on infarct size. 
The use of iodinated radiopaque contrast medium in our 
experiments may be of some concern. Together with the 
thrombotic occlusion/thrombolysis feature of our protocol, 
the use of contrast angiograms made these experiments 
feasible in a closed chest preparation without any previous 
operation for instrumentation. Yet contrast agents have 
recently been shown (30-32) to affect granulocyte function. 
Table 3. Myocardial High Energy Phosphate Content in Postischemic Tissue in 36 Dogs· 
4 h reperfusion 






8.4 ± 6.0 
17.6 ± 3.7 
CrP 
33.5 ± 18.6 






10.7 ± 6.0 
12.2 ± 8.4 
CrP 
36.9 ± 17.2 
16.5 ± 12.2 
'For technical reasons transmural biopsy samples from three dogs in the superoxide dismutase group were not available for analysis. Values are expressed 
in J.tmol/g dry weight. ATP = adenosine triphosphate content; CrP = creatine phosphate content. 
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Inasmuch as neutrophils may contribute to lethal reperfusion 
injury and postischemic stunning of the myocardium, we 
cannot exclude the possibility that the use of contrast 
medium may have had an influence on our results. The role 
of neutrophils in the aforementioned phenomena, however, 
remains controversial (1). 
Effect on infarct size. In assessing the effect of a drug on 
experimental infarct size in a canine model, the variables 
determining the infarct size in the control situation must 
explicitly be taken into account (23,33). This requirement is 
met by the statistical analysis of our data, which reveals the 
area at ris~ and the level of collateral flow to be the only 
predictors of infarct size, without any significant effect of 
superoxide dismutase treatment. With respect to collateral 
flow, it has been argued (5,7) that superoxide dis mutase 
treatment may limit infarct size only in certain subgroups of 
dogs with collateral flow within a specific range. The avail-
able data, however, are contradictory because one study (7) 
found the greatest benefit in those dogs with the lowest 
collateral flow, whereas in the other (5), there was a benefi-
cial effect only in dogs with a higher than average collateral 
flow. 
One problem that this study shares with many previous 
investigations using the canine model is that of statistical 
power. These experiments are difficult, time-consuming and 
expensive and the number of animals must realistically be 
limited. Although it is difficult to associate exact power 
estimates with a multiple regression analysis, the statistical 
power is probably less than desirable, especially for smaller 
reductions in infarct size. Perhaps the time has come for 
someone to attempt a meta-analysis of all available data. 
Postischemic stunning. Postischemic myocardial contrac-
tility could benefit from superoxide dismutase treatment by a 
more rapid recovery of contractile function because oxygen 
free radicals may playa role in the phenomenon of myocar-
dial stunning (34). There was also the question whether a 
possible limitation of infarct size by superoxide dismutase 
would result in better preservation of left ventricular con-
tractility in the long term. To examine these issues, left 
ventricular contractility was measured after different periods 
of reperfusion (4 h, 48 hand 1 week). Because acute 
ischemia, infarction and periinfarction stunning may affect 
global and regional contractility in different ways, measures 
of both global and regional wall motion were analyzed. The 
results expectedly showed a gradual recovery of left ventric-
ular ejection fraction, which was not apparent until after 
48 h. Regional wall motion in the postischemic area recov-
ered with a similar temporal evolution, but to a variable 
degree, depending on the size of the infarction. These 
variables were not affected by superoxide dismutase treat-
ment at any time during reperfusion. Given the lack of 
beneficial effect on infarct size, this outcome was to be 
expected after 1 week; the results after 4 and 48 h imply that 
superoxide dismutase does not alleviate the phenomenon of 
periinfarction myocardial stunning in this model. 
These findings are in agreement with recent studies (15). 
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This inefficacy of superoxide dismutase after prolonged 
ischemia associated with subendocardial infarction is in 
contrast to the results (2-4) obtained after reversible ische-
mia, where free radical scavengers have generally been 
effective in alleviating postischemic stunning. 
Biochemical recovery. We found no evidence of an effect 
of superoxide dismutase treatment on the recovery of the 
high energy phosphate content of postischemic myocardium. 
Individual values depended on the infarct size and we 
observed the expected increase in ATP from 4 h to 1 week of 
reperfusion. The decrease in creatine phosphate content 
from 4 h to 1 week can be ascribed to the overshooting of 
creatine phosphate repletion in viable tissue during the early 
reperfusion phase (35). 
Conclusions. Superoxide dismutase treatment in this ex-
perimental model had no beneficial effect on infarct size or 
postischemic recovery of myocardial contractility and high 
energy phosphate content. This leaves us wondering about 
the missing link between the evidence for a role of oxygen 
radicals in reperfusion injury and the lack of therapeutic 
efficacy of free radical scavengers. 
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